3 results
To evaluate the long-term safety, tolerability and efficacy of ArikaceTM 590 mg for a maximum 12 cycles administered once daily, where each cycle consists of 28 days on treatment followed by 28 days off treatment.
Primary objective- To evaluate the uptake of 68Ga-PSMA in locally advanced, recurrent and metastatic ACC or SDC by performing 68Ga-PSMA-PET/CT scans.Secondary objectives- To calculate the SUV tumor-to-background ratio and tumor-to-*healthy salivary…
Primary Objective1. To evaluate the efficacy of LAI (590 mg) administered once daily (QD), when added to a multi-drug regimen, for achieving culture conversion (3 consecutive monthly negative sputum cultures) by Month 6 compared to a multi-drug…